United States

CSL Biotherapies Starts U.S. Shipments of Influenza Vaccine

First shipments arrive for the 2007/2008 season

King of Prussia, PA — 10/17/2007

CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of influenza vaccine, announced today that it has begun shipment of its influenza virus vaccine in the United States for the 2007-2008 season.

Coming after expedited approval by the United States Food and Drug Administration (FDA) of the inactivated, trivalent vaccine, shipping includes both single-dose, thimerosal-free, pre-filled syringes and multi-dose vials, to provide choice and convenience to caregivers who administer it.

The company will make approximately 2 million doses immediately available to the U.S. market for the 2007/08 season.

"CSL Biotherapies, with a 40-year heritage in influenza vaccines worldwide, is committed to helping address a priority public health goal in the U.S. by providing a reliable supply of high quality flu vaccine, including a thimerosal-free formulation," said Paul Perreault, Executive Vice President of CSL Biotherapies Worldwide Commercial Operations. "We are also supporting efforts to increase vaccination rates with educational programs directed to priority and at-risk audiences, such as health care workers and college students."

About CSL Biotherapies
The U.S. headquarters of CSL Biotherapies are located in King of Prussia, Pa. Its parent company, CSL Limited, in Melbourne, Australia, operates one of the world's largest influenza vaccine facilities for global markets. CSL Biotherapies, which shares its U.S. headquarters with its sister company, CSL Behring, is commercializing influenza vaccine products globally.

CSL-branded influenza vaccines are approved and marketed in 17 countries worldwide, including the U.S. The company also provides bulk antigen for influenza vaccine sold in 24 countries. Last year, CSL, parent company to CSL Biotherapies, announced a $60 million (U.S.D.) investment in plant and equipment to double the manufacturing capacity of the company's Melbourne facility to 40 million doses, making it one of the largest vaccine manufacturing plants in the world. Recently, CSL also announced its intention to expand its fill and finish activities with installation of a new facility in Illinois.

At CSL Biotherapies, delivering vaccines is our mission, protecting lives our passion. The CSL Group, which also includes CSL Research & Development, CSL Bioplasma, and CSL Behring, has more than 8,500 employees and operates in 21 countries worldwide. For more information, visit us at www.cslbiotherapies-us.com, or call 1-888-435-8633.

Media Contacts:
Sheila A. Burke
Director, Public Relations & Communications
Worldwide Commercial Operations
CSL Biotherapies
610-290-7403
484-919-2618 (mobile)
Sheila.Burke@cslbiotherapies.com

Punnie Donohue
Weber Shandwick
212-445-8163
pdonohue@webershandwick.com

The information presented on this site is intended for US residents only.
© 2017 Seqirus All rights reserved.
Seqirus is a trademark of CSL Limited.

BCSL14-02-0003 06/2014